JP2011521969A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521969A5
JP2011521969A5 JP2011511843A JP2011511843A JP2011521969A5 JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5 JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045607 external-priority patent/WO2009146408A1/en
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A JP2011521969A (ja) 2011-07-28
JP2011521969A5 true JP2011521969A5 (cg-RX-API-DMAC7.html) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (cg-RX-API-DMAC7.html)
EP (1) EP2285380A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011521969A (cg-RX-API-DMAC7.html)
CN (1) CN102083439A (cg-RX-API-DMAC7.html)
WO (1) WO2009146408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695511A (zh) * 2009-04-17 2012-09-26 舒玛健康系统有限责任公司 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
MX2013001866A (es) * 2010-08-17 2013-05-22 Allergan Inc Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
US10961508B2 (en) 2013-04-12 2021-03-30 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
EP3042951B1 (en) 2013-09-05 2019-02-20 Kyoto University New method for inducing dopamine-producing neural precursor cells
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3147353B1 (en) 2014-05-21 2022-03-30 Kyoto University Method for producing pancreatic blast cells and pancreatic disease treatment agent containing pancreatic blast cells
WO2017091706A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
EP3447130A4 (en) 2016-04-22 2019-11-13 Kyoto University METHOD FOR PRODUCING DOPAMINE-PROPERING NEURAL PRESERVATOR CELLS
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
JP7161775B2 (ja) 2017-05-25 2022-10-27 国立大学法人京都大学 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法
US20200405768A1 (en) 2018-02-19 2020-12-31 Sumitomo Dainippon Pharma Co., Ltd. Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP3970795A4 (en) 2019-05-15 2023-06-14 Ajinomoto Co., Inc. Method for purifying neural crest cells or corneal epithelial cells
JPWO2020235319A1 (cg-RX-API-DMAC7.html) 2019-05-20 2020-11-26
JP7708373B2 (ja) 2019-09-06 2025-07-15 慶應義塾 グリア前駆細胞を含む細胞凝集体の製造方法
EP4043553A4 (en) 2019-10-01 2023-11-22 Kyoto University METHOD FOR ISOLATING URETERIC BUD TIP CELLS
WO2021187602A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
EP4123015A4 (en) 2020-03-19 2024-05-22 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
JP7429294B2 (ja) 2020-07-13 2024-02-07 国立大学法人京都大学 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法
WO2022149616A1 (ja) 2021-01-08 2022-07-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
JPWO2022259721A1 (cg-RX-API-DMAC7.html) 2021-06-10 2022-12-15
KR20240034191A (ko) 2021-06-17 2024-03-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 인간 다능성 줄기세포 유래 대뇌 피질 세포 제제의 제조 방법
EP4372075A4 (en) 2021-07-15 2025-06-11 Cellfiber Co., Ltd. Structure and use thereof
JPWO2023017848A1 (cg-RX-API-DMAC7.html) 2021-08-11 2023-02-16
JPWO2023149407A1 (cg-RX-API-DMAC7.html) 2022-02-01 2023-08-10
US20250145948A1 (en) 2022-02-09 2025-05-08 Sumitomo Pharma Co., Ltd. Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region
EP4530344A1 (en) 2022-05-23 2025-04-02 Kyoto University Production method for renal collecting duct cells and pelvic epithelial cells
WO2024070494A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 膵内胚葉細胞の製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
EP0670732A1 (en) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
JPH08503969A (ja) * 1993-09-29 1996-04-30 アルコン ラボラトリーズ，インコーポレイテッド 増殖因子と組織形成抑制剤を含有する組成物
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
EP1633718B1 (en) * 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
JP2009519977A (ja) * 2005-12-16 2009-05-21 アルコン，インコーポレイテッド Ａｌｋ５調整剤を用いた眼内圧のコントロール
EP2044056B1 (en) * 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Similar Documents

Publication Publication Date Title
JP2011521969A5 (cg-RX-API-DMAC7.html)
JP2009280627A5 (cg-RX-API-DMAC7.html)
DK2729123T3 (en) Cannabinoidreceptorbindende funds and formations and methods
TWI510235B (zh) 消炎鎮痛外用劑
CA2796575C (en) Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
JP2009102342A5 (cg-RX-API-DMAC7.html)
IL260579A (en) Diagnosis, prevention and treatment of joint diseases
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
WO2007102241A1 (ja) 外用の医薬組成物
JP2014518266A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
HRP20120254T1 (hr) Pripravak za produljenu lokalnu anesteziju koji sadrži saib
TW201141524A (en) Stabilized ophthalmic galactomannan formulations
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
CN104379139A (zh) 贴附剂
CA2717948A1 (en) 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
JP2012508256A5 (cg-RX-API-DMAC7.html)
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
RU2013130026A (ru) Смеси карнозина и гиалуроновой кислоты и их применение
JP2009532373A5 (cg-RX-API-DMAC7.html)
ITMI20071724A1 (it) Formulazioni topiche antivirali in forma di gel bioadesivo
JP2012526099A5 (cg-RX-API-DMAC7.html)
JP2011512362A5 (cg-RX-API-DMAC7.html)